drugset
drugset / Trial / NCT06768658

A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)

NCT06768658 ↗

Phase 1 Terminated 1 enrolled Takeda
RandomizedCrossoverTriple-blindTreatment

Summary

This is a study of TAK-951 in participants with cyclic vomiting syndrome (CVS). The main aims of this study are as follows: * To check for side effects from treatment with TAK-951. * To learn how much TAK-951 participants can receive without getting side effects from it. * To check how much TAK-951 stays in the blood over time to work out the best dose. * The dose of TAK-951 will be checked to see how much stays in their blood over time. * To see if it is possible to give treatment at home. Participants will be given TAK-951 injected just under the skin (subcutaneous or SC).

Timeline

Start
2022-03-02
Primary completion
2023-01-09
Completion
2023-01-09

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-951 Unknown 4 mg Subcutaneous

Indications

No indication recorded.